Project description
A breakthrough solution for heart valve replacement
Heart valve disease poses a significant health challenge, affecting millions of individuals worldwide. Those who suffer from severe aortic valve stenosis require a heart valve replacement. . The heart valves play a vital role in regulating blood flow, and when they become damaged or diseased, they can cause significant health complications. Current solutions, such as mechanical valves and animal tissue-based devices, have limitations in terms of durability, blood compatibility, and delivery methods. To address these issues, the EU-funded Lifelet project will develop a disruptive polymeric heart valve replacement. This innovative device aims to transcend the shortcomings of existing options, providing improved patient outcomes, reduced complications, and cost savings for healthcare systems.
Objective
Lifelet Medical is on a mission to deliver one valve for life for patients suffering from heart valve disease. Lifelet is developing a disruptive polymeric heart valve replacement to transcend the limitations of mechanical and animal tissue-based devices available to patients today. Combining the durability of mechanical valves with the blood compatibility and minimally invasive delivery of animal tissue valves, Lifelet’s fully synthetic device aims to enable improved patient outcomes and reduced complications with easier deliverability, enhanced durability, and cost savings for healthcare systems through automated manufacturing and processing.
There are 1.2 million patients in the U.S. with severe aortic valve stenosis, and over half of these patients are symptomatic, requiring a heart valve replacement. The transcatheter aortic valve replacement (TAVR) market size is €4B, expected to growth to €7B+ by 2024, with a double-digit CAGR. Thanks to recent clinical trials, indications are being expanded for younger patients, asymptomatic patients, and those at low and intermediate risk for surgery, driving growth of the market. Cardiologists will Lifelet's device with existing reimbursement in place. As a platform technology, the Lifelet polymer may also offer clinical benefits in the treatment of obesity, gastrointestinal diseases, and incontinence.
Elle Sander, female CEO and co-founder, is a biomedical engineer who has led the company to a proof-of-principle in chronic sheep studies and is a lead inventor of the material technology, with one patent granted in the EU already. Co-founder and CMO Dr. Faisal Sharif, consultant interventional cardiologist, has a track-record of implanting new devices and a extensive experience of clinical trial development and operations. The team have a passion to commercialise this deep tech, and have the vision to execute on what is required from technical, clinical, regulatory, and commercial perspectives.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- social sciences sociology industrial relations automation
- natural sciences chemical sciences polymer sciences
- medical and health sciences health sciences nutrition obesity
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.2 - European innovation ecosystems
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-CSA - HORIZON Coordination and Support Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIE-2022-SCALEUP-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
H91 RK77 Galway
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.